Highlights from IASLC HTTR 2024

HHTR 2024 took place from December 13-15, 2024, at the Hilton Washington DC National Mall The Wharf.

This dynamic brought together experts and professionals to exchange knowledge and foster collaboration.

IASLC’s Hot Topic Meetings in Basic and Translational Science served as a platform for presenting cutting-edge research, addressing challenges in the field, and exploring collaborative opportunities among academic and industrial researchers to advance the understanding and treatment of NSCLC.

The IASLC 2024 Hot Topic in Basic and Translational Science Meeting was titled “Tolerance and Resistance to Targeted Therapy in Non-Small Cell Lung Cancer”.

The event attracted a multidisciplinary audience, including basic scientists, translational researchers, oncologists, pathologists, molecular biologists, radiologists, pharmaceutical and biotech professionals, academic researchers, and students. This diverse participation reflected the comprehensive approach necessary to tackle the complexities of tolerance and resistance to targeted therapy in NSCLC.

The conference was co-chaired by Alice Berger, William Lockwood, Montse Sanchez-Cespedes and Kenichi Suda.

Stephen V Liu:

“It’s great to see so many IASLC friends in DC at the HTTR24 meeting.”

Christian Rolfo:

“Prof Natasha Leighl giving a great presentation on Liquid Biopsy for TKI monitoring in the 2024 Hot Topic in Basic and Translational Science: Tolerance and Reseistance to Targeted Therapies.”

Anika Patel:

“KRAS inhibition clearly has potential to increase immune inflammation in the right preclinical models. Looking forward to hearing more about where this research takes us.”

Stephen V Liu:

“Dr. Katerina Politi at IASLC HTTR24 discusses use of in vivo models to study drug resistance and tolerance. Intriguing work on EGFR resistance and SMARCA4, SWI/SNF, even ASCL1.”

Christian Rolfo:

“Excellent HTTR24 Meeting with incredible discussions and insights on biomarkers research. Thanks IASLC for the invitation to present liquid biopsy contribution. Great opportunity to networking and meet good friends. Congrats to the chairs!”

Jennifer C. King:

“I’m learning so much about lineage plasticity at HTTR24 – this has been a fabulous session of advances in cancer biology!”

Stephen V Liu:

“Brilliant discussion of clonal dynamics with regard to resistance to targeted therapies by Dr. Aaron Hata at the IASLC HTTR24 meeting. Clones can pre-exist and also evolve. Different scenarios likely for early vs late progression.”

Jennifer C. King:

“That’s a wrap on HTTR24 in DC! It was a fantastic, collaborative meeting on resistance to lung cancer therapeutics – and the hashtag wasn’t actually a shoutout to the Washington Commanders ! Thanks to everyone who participated.”

Tadashi Manabe:

“I had a wonderful time at HTTR24, IASLC! Yesterday, I had the opportunity to present our recent work on Exarafenib, a novel therapeutic approach that addresses a critical unmet need in BRAF-mutated lung cancer. Thanks to all the researchers who shared their insights!”

Rodrigo Paredes:

“Thank you so much, Christian Rolfo, for the incredible support and mentorship. It’s truly an honor to present our work at HTTR24 and share these important findings. Your guidance has been invaluable in shaping this project!”

Stephen V Liu:

“Dr. Ming-Sound Tsao discusses the role of patient derived xenografts (PDX) to study drug resistance at the IASLC HTTR24 meeting. Some advantages over cell lines but also some challenges. Will this help us understand drug tolerant persister populations?”